Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL

Salim Yazji • 10 Jun 2022
EHA 2022
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Zilovertamab vedotin
ZILO-301

Salim Yazji, MD, Oncternal Therapeutics, San Diego, CA, comments on the rationale and design of ZILO-301, a Phase III study comparing the safety and efficacy of zilovertamab plus ibrutinib vs ibrutinib alone in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) (NCT05431179). Dr Yazji also briefly talks on a ROR1-directed CAR-T therapy that is currently being developed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Oncternal Therapeutics

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals